Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PGPR Improves Barley Performance Under Saline Irrigation: Agronomic, Biochemical, and Transcriptional Evidence from a Two-Season Field Study.

Plants (Basel, Switzerland)·2026

Same author

Correction: Correlation analysis of electronic health literacy, compliance behavior, and quality of life in middle-aged and older patients with coronary heart disease: a cross-sectional study.

Frontiers in public health·2026

Same author

Nanotechnology-mediated precision delivery of mRNA.

Nature materials·2026

Same author

Computed tomography enterography-based deep learning radiomics models of intestinal lesions and perienteric fat for predicting Crohn's disease activity: a multicenter cohort study.

Quantitative imaging in medicine and surgery·2026

Same author

Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures.

Polymer science & technology (Washington, D.C.)·2026

Same author

Correction to "Triphase Interface Synthesis of Plasmonic Gold Bellflowers as Near-Infrared Light Mediated Acoustic and Thermal Theranostics".

Journal of the American Chemical Society·2026

Same journal

A pH-Tolerant Nickel-Vanadium Phosphonate Framework for Stable Aqueous Supercapacitor Cycling.

ACS nano·2026

Same journal

Reconfigurable Photoelectric Coaxial Fiber-Based Memristors for Neuromorphic Computing.

ACS nano·2026

Same journal

Multidimensional Emission Control of CsPbI<sub>3</sub> Quantum Dots Using Plasmonic Quasi-Bound States in the Continuum.

ACS nano·2026

Same journal

Reconfigurable 2D Floating-Gate Field-Effect Transistors with Graphene-Induced Interfacial Polarization for Unified Memory-Logic Integration.

ACS nano·2026

Same journal

Bioinstructive Hybrid Scaffold Integrating Phosphoinositide 3-Kinase-Akt and Complementary Survival Pathways for Kidney Regeneration.

ACS nano·2026

Same journal

Robust Quantum Cutting via Halide-Bearing Ligand Passivation and Gradient Halide Reconstruction for Ultrabroadband Ultraviolet-to-Near-Infrared Photodetection and Imaging.

ACS nano·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 11, 2025

Biological Compatibility Profile on Biomaterials for Bone Regeneration

Published on: November 16, 2018

Boosting Checkpoint Immunotherapy with Biomaterials.

Lujie Liu^1,2, Yuanwei Pan^2,3, Chenchen Zhao²

¹Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen 518060, China.

|February 6, 2023

Summary

This summary is machine-generated.

Biomaterials enhance immune checkpoint blockade (ICB) cancer therapy by improving efficacy and reducing toxicity. This review explores design strategies for biomaterials to boost ICB treatment outcomes.

Keywords:

biomaterials cancer immunotherapy drug delivery extracellular vesicles genetic engineering immune checkpoint blockade immunomodulation nanotechnology

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Aug 11, 2025

Biological Compatibility Profile on Biomaterials for Bone Regeneration

Published on: November 16, 2018

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

Biomedical Engineering
Immunology
Materials Science

Background:

Immune checkpoint blockade (ICB) therapy offers a revolutionary approach to cancer treatment.
However, limited response rates and significant systemic toxicity hinder its clinical success.
Biomaterials present a promising avenue to overcome these limitations.

Purpose of the Study:

To review current design strategies of biomaterials for augmenting ICB therapy.
To discuss biomaterial-assisted immune modulation and targeted delivery of checkpoint inhibitors.
To summarize challenges and future prospects for biomaterial integration with ICB therapy.

Main Methods:

Comprehensive literature review of biomaterial design for ICB therapy.
Analysis of biomaterial-mediated immune modulation strategies.
Evaluation of targeted delivery systems for checkpoint inhibitors.

Main Results:

Biomaterials can enhance tumor antigenicity and reverse immunosuppressive microenvironments.
They amplify antitumor immune responses and improve checkpoint inhibitor delivery and retention.
Various biomaterial types show potential for maximizing therapeutic efficacy and minimizing side effects.

Conclusions:

Biomaterials offer significant potential to enhance the effectiveness of immune checkpoint blockade therapy.
Strategic design of biomaterials can overcome current limitations of ICB treatment.
Further development and clinical application of biomaterial-assisted ICB therapy are anticipated.